2327 GMT [Dow Jones]--Cochlear's lineup of new products turns UBS analysts bullish on the stock. They upgrade their recommendation on the hearing-tech manufacturer to buy from neutral, telling clients in a note that they expect its new implant portfolio to deliver global market share gains and 10% compound annual revenue growth from implants over the next three years. They also see services revenue rising 40% over three years from a higher installed base and as customers replace processors. UBS raises its target price 14% to A$325.00. Shares are at A$281.66 ahead of the open. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
June 17, 2025 19:34 ET (23:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。